Cargando…

Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches

Neoantigens generated by non-synonymous mutations of tumor genes can induce activation of neoantigen-reactive T (NRT) cells which have the ability to resist the growth of tumors expressing specific neoantigens. Immunotherapy based on NRT cells has made preeminent achievements in melanoma and other s...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ruichen, Zhao, Bi, Hu, Shi, Zhang, Qian, Su, Xiaoping, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108522/
https://www.ncbi.nlm.nih.gov/pubmed/37062844
http://dx.doi.org/10.1186/s40364-023-00478-5
_version_ 1785026866029002752
author Huang, Ruichen
Zhao, Bi
Hu, Shi
Zhang, Qian
Su, Xiaoping
Zhang, Wei
author_facet Huang, Ruichen
Zhao, Bi
Hu, Shi
Zhang, Qian
Su, Xiaoping
Zhang, Wei
author_sort Huang, Ruichen
collection PubMed
description Neoantigens generated by non-synonymous mutations of tumor genes can induce activation of neoantigen-reactive T (NRT) cells which have the ability to resist the growth of tumors expressing specific neoantigens. Immunotherapy based on NRT cells has made preeminent achievements in melanoma and other solid tumors. The process of manufacturing NRT cells includes identification of neoantigens, preparation of neoantigen expression vectors or peptides, induction and activation of NRT cells, and analysis of functions and phenotypes. Numerous improvement strategies have been proposed to enhance the potency of NRT cells by engineering TCR, promoting infiltration of T cells and overcoming immunosuppressive factors in the tumor microenvironment. In this review, we outline the improvement of the preparation and the function assessment of NRT cells, and discuss the current status of clinical trials related to NRT cell immunotherapy.
format Online
Article
Text
id pubmed-10108522
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101085222023-04-18 Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches Huang, Ruichen Zhao, Bi Hu, Shi Zhang, Qian Su, Xiaoping Zhang, Wei Biomark Res Review Neoantigens generated by non-synonymous mutations of tumor genes can induce activation of neoantigen-reactive T (NRT) cells which have the ability to resist the growth of tumors expressing specific neoantigens. Immunotherapy based on NRT cells has made preeminent achievements in melanoma and other solid tumors. The process of manufacturing NRT cells includes identification of neoantigens, preparation of neoantigen expression vectors or peptides, induction and activation of NRT cells, and analysis of functions and phenotypes. Numerous improvement strategies have been proposed to enhance the potency of NRT cells by engineering TCR, promoting infiltration of T cells and overcoming immunosuppressive factors in the tumor microenvironment. In this review, we outline the improvement of the preparation and the function assessment of NRT cells, and discuss the current status of clinical trials related to NRT cell immunotherapy. BioMed Central 2023-04-17 /pmc/articles/PMC10108522/ /pubmed/37062844 http://dx.doi.org/10.1186/s40364-023-00478-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Huang, Ruichen
Zhao, Bi
Hu, Shi
Zhang, Qian
Su, Xiaoping
Zhang, Wei
Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
title Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
title_full Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
title_fullStr Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
title_full_unstemmed Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
title_short Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
title_sort adoptive neoantigen-reactive t cell therapy: improvement strategies and current clinical researches
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108522/
https://www.ncbi.nlm.nih.gov/pubmed/37062844
http://dx.doi.org/10.1186/s40364-023-00478-5
work_keys_str_mv AT huangruichen adoptiveneoantigenreactivetcelltherapyimprovementstrategiesandcurrentclinicalresearches
AT zhaobi adoptiveneoantigenreactivetcelltherapyimprovementstrategiesandcurrentclinicalresearches
AT hushi adoptiveneoantigenreactivetcelltherapyimprovementstrategiesandcurrentclinicalresearches
AT zhangqian adoptiveneoantigenreactivetcelltherapyimprovementstrategiesandcurrentclinicalresearches
AT suxiaoping adoptiveneoantigenreactivetcelltherapyimprovementstrategiesandcurrentclinicalresearches
AT zhangwei adoptiveneoantigenreactivetcelltherapyimprovementstrategiesandcurrentclinicalresearches